Core Insights - Quantum eMotion Corp. has converted $350,000 in debt into equity and made an additional investment of $350,000 in Greybox Solutions Inc., becoming the second-largest shareholder in the company [1][2] - This strategic investment reflects Quantum eMotion's confidence in Greybox's growth in the Remote Care Management and Digital Therapeutics sector, particularly following the launch of the TakeCareTM platform [2][4] - The digital therapeutics market is projected to grow at over 20% CAGR globally, indicating significant potential for both companies [4] Company Overview - Greybox Solutions is a Montreal-based health technology company focused on innovative software development aimed at improving patient care and addressing healthcare system challenges [5] - The TakeCareTM platform is designed to enhance the relationship between patients and healthcare teams, positioning Greybox as a leader in digital health [5] - Quantum eMotion specializes in cybersecurity solutions, leveraging its patented Quantum Random Number Generator technology to provide enhanced protection for critical systems [6][7] Strategic Partnership - The partnership between Quantum eMotion and Greybox Solutions is strengthened by Quantum's Sentry-Q cybersecurity platform, which secures the TakeCareTM platform [3][4] - The appointment of Quantum eMotion's CEO, Francis Bellido, to Greybox's Board of Directors is expected to enhance strategic alignment and access to a broader healthcare network [4] - This collaboration emphasizes the importance of building a trusted, quantum-safe infrastructure for the future of digital therapeutics [4]

Company Overview - Sonim Technologies, Inc. is a leading provider of rugged mobile solutions, including phones, wireless internet data devices, accessories, and software designed for durability in demanding environments [3] - The company has been trusted by first responders, government, and Fortune 500 customers since 1999, selling its products through tier one wireless carriers and distributors in North America, EMEA, and Australia/New Zealand [3] Proposed Transaction - Sonim Technologies has issued an update regarding a Letter of Intent (LOI) for a proposed reverse takeover (RTO) with a private US-based company that is developing Nvidia-based High-Performance Computing (HPC) AI factories [1][2] - Upon completion of the RTO, Sonim shareholders will receive equity ownership in the combined company, currently valued at $17.5 million, with potential for future value appreciation [2] Commitment to Transparency - The announcement reflects Sonim's commitment to transparency as the transaction progresses, with further updates to be shared as more information becomes available [2]

Core Viewpoint - Medicus Pharma Ltd has entered into a definitive agreement to acquire Antev Ltd, a UK-based clinical-stage drug development company, with Antev shareholders receiving approximately 17% equity stake in Medicus and up to US$65 million in contingent payments tied to future FDA approvals [1][4]. Group 1: Transaction Details - Medicus will acquire all issued and outstanding Antev Shares in exchange for 2,666,600 Medicus common shares, representing approximately 17% of the total shares [2]. - The transaction is expected to close by the end of August 2025, pending certain closing conditions including shareholder approval [5]. - Antev shareholders will be subject to a 9-month staggered lock-up and will grant voting rights to Medicus management for 36 months [3]. Group 2: Antev's Product Pipeline - Antev is developing Teverelix, a next-generation GnRH antagonist, targeting high-risk prostate cancer patients and those experiencing acute urinary retention due to enlarged prostate [6][14]. - Teverelix aims to prevent recurrence of acute urinary retention in men aged 45 and older, with a potential market opportunity exceeding US$2 billion annually [7]. - The FDA has approved a Phase 2b study for Teverelix in acute urinary retention, involving 390 participants [19]. Group 3: Market Potential - For advanced prostate cancer patients with increased cardiovascular risk, Teverelix presents a potential market opportunity of over US$4 billion annually, targeting 300,000 to 500,000 men in the US [10]. - Teverelix is designed to provide a hormone therapy option with potentially lower cardiac toxicity compared to conventional treatments [15]. Group 4: Clinical Development - Antev has completed a Phase 1 clinical trial for Teverelix, demonstrating good tolerance and rapid testosterone suppression [16]. - The company has also completed a Phase 2a study, achieving a primary endpoint of over 90% testosterone suppression but not maintaining this rate beyond 42 days [17]. - The FDA has provided guidance on Antev's proposed Phase 3 trial design for Teverelix, supporting its clinical development plans [18].

Core Insights - Stardust Solar Energy Inc. reported a revenue of $3.61 million for 2024, marking a 38% increase from 2023, driven primarily by the U.S. franchise segment which saw a remarkable 483% year-over-year growth [2][4]. Financial Performance - The company incurred one-time costs of $0.99 million related to professional fees and a non-cash reverse-takeover transaction cost of $3.90 million during its public-listing process, which are expected to decline significantly in 2025 [3][4]. Business Expansion - Stardust Solar expanded its franchise territories from 27 to 83 in 2024, and currently operates in 94 territories across North America. Strategic partnerships with Tesla and Rematek Energie have bolstered support for franchisees [4][5]. Future Outlook - Management anticipates continued revenue growth in 2025, fueled by deeper market penetration in the U.S., direct procurement of equipment, and the launch of a mobile certification application aimed at enhancing installer training [4][5].

Group 1 - Baytex Energy Corp. has successfully extended its US$1.1 billion revolving credit facilities by one year, moving the maturity date from May 2028 to June 2029 [1] - The revolving credit facilities are not classified as borrowing base facilities and do not require annual or semi-annual reviews, indicating a stable financial position [1] Group 2 - Baytex Energy Corp. is an energy company based in Calgary, Alberta, with operations in the acquisition, development, and production of crude oil and natural gas [2] - The company operates primarily in the Western Canadian Sedimentary Basin and the Eagle Ford region in the United States [2] - Baytex's common shares are traded on both the Toronto Stock Exchange and the New York Stock Exchange under the symbol BTE [2]

CORRECTION FROM SOURCE: Quantum eMotion Announces Successful Completion of Quantum Simulation Project Evaluating Sentry-Q Cryptographic ArchitectureJune 27, 2025 12:16 PM EDT | Source: Quantum eMotion Corp.This news release corrects and replaces the news release that was issued by Quantum eMotion Corp. on June 26, 2025 - PINQ2 boilerplate and quote added. There are no material changes to the previous news release. Montreal, Quebec--(Newsfile Corp. - June 27, 2025) - Quantum eMotion Corp. (TSXV ...

Masivo Highlights Wide Historic High-Grade Results from Cerro Colorado and Announces Equity RaiseJune 27, 2025 11:30 AM EDT | Source: Masivo Silver Corp.Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - Masivo Silver Corp. (TSXV: MASS) (OTC Pink: GNYPF) ("Masivo" or the "Company") is pleased to report encouraging historic results from the two known drill holes completed at the drill target for Cerro Colorado Gold-Silver Project in Sonora, Mexico, as the Company advances final due ...

No stockholder action required at this timeSan Diego, California--(Newsfile Corp. - June 27, 2025) - The Special Committee of the Board of Directors (the "Special Committee") of Sonim Technologies, Inc. (NASDAQ: SONM), formed to oversee the Company's ongoing strategic alternatives process, today confirmed receipt of an unsolicited, non-binding proposal from Orbic North America, LLC to acquire substantially all of Sonim's operating assets for $25 million. The proposal, dated June 26, 2025, represented that ...

Core Viewpoint - Goldstorm Metals Corp. has successfully closed a non-brokered private placement financing, raising approximately $2.1 million, with notable participation from strategic investor Eric Sprott [2][5]. Financing Details - The private placement generated gross proceeds of $2,088,973.75, consisting of 15,441,483 non-flow-through units sold at $0.07 each, totaling $1,080,903.81, and 9,999,999 flow-through units sold at $0.1008 each, totaling $1,007,999.90 [2][3]. - Each non-flow-through unit includes one common share and one-half of a warrant, while each flow-through unit includes one common share and one-half of a warrant [3]. Warrant Information - Each warrant allows the holder to purchase one common share at an exercise price of $0.10 for 24 months, with an acceleration clause if the common shares reach a closing price of $0.20 for ten consecutive trading days [4]. Strategic Investor Participation - Eric Sprott, through his corporation, acquired 3,571,428 common shares and 1,785,714 warrants, qualifying as a related-party transaction [5]. Use of Proceeds - Net proceeds from the sale of non-flow-through units will be allocated for working capital and general corporate purposes [6]. - Gross proceeds from flow-through units will be used for Canadian exploration expenses, with a commitment to incur qualifying expenditures by December 31, 2026 [7]. Finder's Fees - The company paid cash commissions of $45,746.44 to finders and issued 651,377 non-transferable finder's warrants, each allowing the purchase of one common share at $0.1008 for 24 months [8][9]. Company Overview - Goldstorm Metals Corp. is focused on precious and base metals exploration, holding a significant land position in British Columbia's Golden Triangle, known for high-grade gold deposits [10].

Core Viewpoint - Kenorland Minerals Ltd. has announced the termination of its joint venture with Newmont Corporation regarding the Healy project in Alaska, while also completing a top-up right exercise with Sumitomo and Centerra to maintain their respective interests in the company [2][3]. Group 1: Joint Venture Termination - Newmont Corporation has delivered a notice to terminate the joint venture agreement for the Healy project in Alaska [2]. - Kenorland has fully vested a 70% interest in the Healy project, but both parties have decided not to pursue further exploration [2]. - The Healy claims will be allowed to lapse due to the costs associated with maintaining the claims and Kenorland's focus on higher priority exploration projects [2]. Group 2: Top-Up Right Completion - Kenorland, along with Sumitomo Metal Mining Canada Ltd. and Centerra Gold Inc., has completed the exercise of the 'top-up right' to retain their interests of 10.1% and 9.9% in the company, respectively [3]. - A total of 257,737 common shares were issued for an aggregate consideration of $408,162.85, with shares priced at $1.598 and $1.473 [4]. - The shares issued are subject to a statutory hold period expiring on October 27, 2025 [4]. Group 3: Related Party Transaction - Sumitomo, owning more than 10% of Kenorland's outstanding shares, is classified as a "related party" under Multilateral Instrument 61-101 [5]. - The transaction is considered a "related party transaction" as defined by MI 61-101 [5]. - Kenorland has relied on exemptions from formal valuation and minority shareholder approval requirements due to the fair market value of the transaction not exceeding 25% of the company's market capitalization [6]. Group 4: Company Overview - Kenorland Minerals Ltd. is a well-financed mineral exploration company focused on project generation and early-stage exploration in North America [8]. - The company's exploration strategy involves advancing greenfields projects through systematic exploration surveys, primarily financed through exploration partnerships [8]. - Kenorland holds a 4% net smelter return royalty on the Frotet Project in Quebec, which is owned by Sumitomo Metal Mining Canada Ltd. [8].